FGFR1 amplification in HR+ breast cancer (~10-15%): prognostic for endocrine-therapy resi...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-FGFR1-AMP-BREAST |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-BREAST |
| Sources | SRC-CIVIC SRC-ESMO-BREAST-METASTATIC-2024 SRC-NCCN-BREAST-2025 |
Actionability Facts
| Biomarker | BIO-FGFR1 |
|---|---|
| Variant | amplification (~10-15% HR+ breast) |
| Disease | DIS-BREAST |
| ESCAT tier | IV |
| Recommended combinations | clinical trial (novel FGFR / endocrine combinations) |
| Evidence summary | FGFR1 amplification in HR+ breast cancer (~10-15%): prognostic for endocrine-therapy resistance and reduced PFS on aromatase inhibitor. Therapeutic actionability is unproven — multiple FGFR-TKI trials (lucitanib FINESSE, dovitinib) negative or marginal. No FGFR-targeted drug approved for breast cancer. |
Notes
ESCAT IV (prognostic / hypothetical clinical actionability). OncoKB Level 4. Standard 1L HR+/HER2- metastatic breast remains CDK4/6i + endocrine; FGFR1-amp does not currently modify treatment selection.
Used By
No reverse references found in the YAML corpus.